APA (7th ed.) Citation

Qiao Liu, Zhen Zhou, Xia Luo, Lidan Yi, Liubao Peng, Xiaomin Wan, . . . Xiaohui Zeng. (2022). Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Qiao Liu, Zhen Zhou, Xia Luo, Lidan Yi, Liubao Peng, Xiaomin Wan, Chongqing Tan, and Xiaohui Zeng. Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%. Frontiers Media S.A., 2022.

MLA (9th ed.) Citation

Qiao Liu, et al. Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%. Frontiers Media S.A., 2022.